NextCure, Inc.
NXTC- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001661059
In the last 90 days, NextCure, Inc. insiders filed 2 open-market purchases and 1 sale; 30 institutions reported holding it in 13F filings for Q2 2026, worth $2.78M in total; no superinvestor holds it.
Q1 2025 vs. Q4 2024
How the institutions holding NextCure, Inc. changed between Q4 2024 and Q1 2025.
All holders in Q1 2025All holders in Q4 2024
| Measure | Q4 2024 | Q1 2025 | Change |
|---|---|---|---|
| Holders | 46 | 38 | −8 |
| Shares | 16.0M | 15.4M | −669.8K (−4.2%) |
| Value | $13.1M | $7.38M | −$5.75M (−43.8%) |
New holders (0)
Institutions that held NextCure, Inc. at the end of Q1 2025 but not at the end of Q4 2024.
None.
Sold out (8)
Institutions that held NextCure, Inc. at the end of Q4 2024 and filed for Q1 2025 without it.
| Institution | Shares, Q4 2024 | Value, Q4 2024 |
|---|---|---|
| Long Focus Capital Management, LLC | 185,936 | $143.4K |
| Hudson Bay Capital Management LP | 107,672 | $83.0K |
| Marquette Asset Management, LLC | 58,259 | $44.9K |
| Susquehanna International Group, LLP | 48,186 | $37.2K |
| Virtu Financial LLC | 22,951 | $18.0K |
| LPL Financial LLC | 20,500 | $15.8K |
| Advisor Group Holdings, Inc. | 1,191 | $917 |
| Morgan Stanley | 1 | $1 |